| dc.contributor.author | Asfuroğlu, Mahmut | |
| dc.contributor.author | Çavdarlı, Büşranur | |
| dc.contributor.author | Gürbüz Koz, Özlem | |
| dc.contributor.author | Yarangümeli, Ahmet | |
| dc.contributor.author | Özdemir, Emine | |
| dc.date.accessioned | 2019-05-13T08:58:56Z | |
| dc.date.available | 2019-05-13T08:58:56Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Asfuroğlu, M., Çavdarlı, B., Gürbüz Koz, Ö., Yarangümeli, A., Özdemir, E. (2017). In Reply. Journal of Glaucoma, 26(7), 685-688. | en_US |
| dc.identifier.issn | 1057-0829 | |
| dc.identifier.uri | https://doi.org/10.1097/IJG.0000000000000673 | |
| dc.identifier.uri | https://hdl.handle.net/11491/1224 | |
| dc.description.abstract | I am thankful to you for giving me this opportunity to respond this letter to the editor. I read the recent article by Yılmaz and colleagues entitled “LOXL1 gene analysis in Turkish patients with exfoliation glaucoma.” In this study they analyzed whole LOXL1 gene by sequence analysis to detect any mutations or additional polymorphisms with pseudoexfoliation (PEX) glaucoma in 48 Turkish patients | en_US |
| dc.language.iso | eng | |
| dc.publisher | Lippincott Williams and Wilkins | en_US |
| dc.relation.isversionof | 10.1097/IJG.0000000000000673 | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | [Belirlenecek] | en_US |
| dc.title | In Reply | en_US |
| dc.type | other | en_US |
| dc.relation.journal | Journal of Glaucoma | en_US |
| dc.department | Hitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü | en_US |
| dc.identifier.volume | 26 | en_US |
| dc.identifier.issue | 7 | en_US |
| dc.identifier.startpage | 685 | en_US |
| dc.identifier.endpage | 686 | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
